A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration

[1]  P. Xie,et al.  Genetic Association with Response to Intravitreal Ranibizumab for Neovascular Age-Related Macular Degeneration in the Han Chinese Population , 2013, Ophthalmologica.

[2]  S. Piermarocchi,et al.  Combined effects of genetic and non‐genetic risk factors affect response to ranibizumab in exudative age‐related macular degeneration , 2015, Acta ophthalmologica.

[3]  M. Savolainen,et al.  INTERLEUKIN 8 PROMOTER POLYMORPHISM PREDICTS THE INITIAL RESPONSE TO BEVACIZUMAB TREATMENT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION , 2013, Retina.

[4]  W. Berger,et al.  Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD. , 2011, Investigative ophthalmology & visual science.

[5]  H. Aounallah-Skhiri,et al.  Y402H Polymorphism in Complement Factor H and Age-Related Macular Degeneration in the Tunisian Population , 2013, Ophthalmic Research.

[6]  U Chakravarthy,et al.  The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. , 2014, Ophthalmology.

[7]  Dae Hyun Lee,et al.  Pharmacogenetic Influence of LOC387715/HTRA1 on the Efficacy of Bevacizumab Treatment for Age-Related Macular Degeneration in a Korean Population , 2012, Korean journal of ophthalmology : KJO.

[8]  Jiayan Huang,et al.  VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). , 2014, JAMA ophthalmology.

[9]  I. Constable,et al.  Complement factor H Y402H and C-reactive protein polymorphism and photodynamic therapy response in age-related macular degeneration. , 2009, Ophthalmology.

[10]  M. Brantley,et al.  Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to photodynamic therapy , 2009, Eye.

[11]  A. Tsujikawa,et al.  Two-year visual outcome of ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy , 2015, Graefe's Archive for Clinical and Experimental Ophthalmology.

[12]  Yonghua Hu,et al.  Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population. , 2012, Pharmacogenomics.

[13]  R. González-Sarmiento,et al.  Predictive value of VEGF A and VEGFR2 polymorphisms in the response to intravitreal ranibizumab treatment for wet AMD , 2014, Graefe's Archive for Clinical and Experimental Ophthalmology.

[14]  P. Tommila,et al.  The Effect of Complement Factor H Y402H Polymorphism on the Outcome of Photodynamic Therapy in Age-related Macular Degeneration , 2007, European journal of ophthalmology.

[15]  P. Tommila,et al.  Vascular endothelial growth factor gene variation and the response to photodynamic therapy in age-related macular degeneration. , 2010, Ophthalmology.

[16]  R. Yamada,et al.  Genetic variants in pigment epithelium-derived factor influence response of polypoidal choroidal vasculopathy to photodynamic therapy. , 2011, Ophthalmology (Rochester, Minn.).

[17]  Ivana K. Kim,et al.  Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). , 2013, Ophthalmology.

[18]  Chun-Fang Xu,et al.  GENETIC FACTORS ASSOCIATED WITH RESPONSE TO INTRAVITREAL RANIBIZUMAB IN KOREAN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2014, Retina.

[19]  M. McKibbin,et al.  CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration , 2011, British Journal of Ophthalmology.

[20]  I. Chowers,et al.  Sequence variants in HTRA1 and LOC387715/ARMS2 and phenotype and response to photodynamic therapy in neovascular age-related macular degeneration in populations from Israel , 2008, Molecular vision.

[21]  A. Tsujikawa,et al.  VEGF gene polymorphism and response to intravitreal bevacizumab and triple therapy in age-related macular degeneration , 2011, Japanese Journal of Ophthalmology.

[22]  Christoph Ehlken,et al.  Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV , 2016, British Journal of Ophthalmology.

[23]  J. Jonas,et al.  Role of vascular endothelial growth factor polymorphisms in the treatment success in patients with wet age-related macular degeneration. , 2012, Ophthalmology.

[24]  A. Tsujikawa,et al.  Factors Associated with Recurrence of Age-Related Macular Degeneration after Anti-Vascular Endothelial Growth Factor Treatment: A Retrospective Cohort Study. , 2015, Ophthalmology.

[25]  J. Duker,et al.  Predictors of Response to Intravitreal Anti-Vascular Endothelial Growth Factor Treatment of Age-Related Macular Degeneration. , 2015, American journal of ophthalmology.

[26]  K. Kadonosono,et al.  Comparison of Time to Retreatment and Visual Function Between Ranibizumab and Aflibercept in Age-Related Macular Degeneration. , 2016, American journal of ophthalmology.

[27]  Aaron Y. Lee,et al.  Common variants near FRK/COL10A1 and VEGFA are associated with advanced age-related macular degeneration , 2011, Human molecular genetics.

[28]  G. Ying,et al.  Outer retinal tubulation in the comparison of age-related macular degeneration treatments trials (CATT). , 2014, Ophthalmology.

[29]  A. Tsujikawa,et al.  Retinal Pigment Epithelial Atrophy in Neovascular Age-Related Macular Degeneration After Ranibizumab Treatment. , 2016, American journal of ophthalmology.

[30]  R. Guymer,et al.  Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study. , 2015, Ophthalmology.

[31]  R. Guymer,et al.  Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration. , 2013, Ophthalmology.

[32]  W. Wood,et al.  A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration , 2013, Clinical ophthalmology.

[33]  K. Horie-Inoue,et al.  Complement factor H and high-temperature requirement A-1 genotypes and treatment response of age-related macular degeneration. , 2011, Ophthalmology.

[34]  M. Nardi,et al.  Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration. , 2012, Pharmacogenomics.

[35]  Glenn J Jaffe,et al.  Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. , 2015, Ophthalmology.

[36]  Arto Luoma,et al.  The IL-8, VEGF, and CFH polymorphisms and bevacizumab in age-related macular degeneration. , 2014, Ophthalmology.

[37]  I. Chowers,et al.  Association of complement factor H Y402H polymorphism with phenotype of neovascular age related macular degeneration in Israel , 2008, Molecular vision.

[38]  R. Avery,et al.  Common variant in VEGFA and response to anti-VEGF therapy for neovascular age-related macular degeneration. , 2013, Current molecular medicine.

[39]  M. Brantley,et al.  Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. , 2007, Ophthalmology.

[40]  A. Tsujikawa,et al.  Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment. , 2011, American journal of ophthalmology.

[41]  Gary C. Brown,et al.  ASSOCIATION BETWEEN HIGH-RISK DISEASE LOCI AND RESPONSE TO ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT FOR WET AGE-RELATED MACULAR DEGENERATION , 2012, Retina.

[42]  G. Ying,et al.  Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. , 2015, Ophthalmology.

[43]  S. Harding,et al.  Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN Study. , 2013, Ophthalmology.

[44]  Dennis Andersson,et al.  A retrospective cohort study , 2018 .

[45]  B. J. Klevering,et al.  Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration. , 2012, Ophthalmology.

[46]  S. Teper,et al.  Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration , 2010, Molecular vision.

[47]  Masahiro Miyake,et al.  Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy , 2015, Graefe's Archive for Clinical and Experimental Ophthalmology.

[48]  M. Sagong,et al.  Pharmacogenetic association with early response to intravitreal ranibizumab for age-related macular degeneration in a Korean population , 2013, Molecular vision.

[49]  R. Neal PROJECT ADMINISTRATION , 2009 .

[50]  Kang Zhang,et al.  Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). , 2013, Ophthalmology.

[51]  Yonghua Hu,et al.  Predictors of Visual Response to Intravitreal Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration , 2013, Journal of ophthalmology.

[52]  K. Horie-Inoue,et al.  CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degeneration , 2010, Journal of ocular biology, diseases, and informatics.